RxDoctor Payments Data

Amie Coffman, DO

Neurology · Meadville, PANPI 1760894422

Payments from drug & device makers

$8,565in general payments, 2019–2025

Across 402 payments — averaging $21.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Boston Scientific$1K
  • Biogen$490
  • Ipsen Biopharmaceuticals, Inc$451
  • Sanofi$424
  • Teva Pharmaceuticals USA, Inc.$372
  • plus $4K from 47 others

What the payments were for

  • Speaking & faculty fees$2523%
  • Travel & lodging$86410%
  • Food & beverage$7,20484%
  • Education$2453%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,565 in reported general payments places this provider in the 70th percentile of 941 neurology providers in Pennsylvania.

See all neurology providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$51,584
Medicare patients
273
Services billed
546

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Teriflunomide21$84,510
GlatopaGlatiramer Acetate16$72,160
Emgality PenGalcanezumab-Gnlm67$47,100
Dimethyl Fumarate12$45,924
Nurtec OdtRimegepant Sulfate36$45,393
RytaryCarbidopa/Levodopa19$21,267
Aimovig AutoinjectorErenumab-Aooe29$20,474
NeuproRotigotine25$20,405
Lacosamide98$16,574
EliquisApixaban12$6,985
AmantadineAmantadine Hcl71$5,101
Levetiracetam103$4,998
Dalfampridine ErDalfampridine11$4,715
Carbidopa-LevodopaCarbidopa/Levodopa220$4,064
Rivastigmine25$3,496

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerNurtec Odt, Eliquis$320$52,37848 claims
Amneal Pharmaceuticals LLCRytary, Pyridostigmine Bromide$82$23,05544 claims
UCB, Inc.Neupro$249$20,40525 claims
Upsher-smith Laboratories LLCTopiramate$61$1,09383 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 941 neurology providers in Pennsylvania.

Other neurology in Meadville

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →